Home Dialysis Module Cases

Dialysis Prescription & Complications

HD Prescription, Vascular Access, Intradialytic Complications & First Dialysis Considerations

Prescription Adequacy Vascular Access Complications Disequilibrium

Quick Navigation

HD Prescription Adequacy (Kt/V, URR) Urgent Indications Vascular Access Intradialytic Complications Disequilibrium Syndrome First Dialysis

Hemodialysis Prescription Components

The HD prescription specifies all parameters needed to deliver safe and effective renal replacement therapy. Each element influences solute clearance, fluid removal, electrolyte management, and hemodynamic tolerance.

Core Prescription Parameters

Blood Flow Rate (Qb)

Range: 300–450 mL/min

Higher Qb maintains concentration gradients and reduces recirculation. The relationship with clearance is curvilinear—diminishing returns above ~400 mL/min due to membrane limitations. Must match vascular access capacity.

Dialysate Flow Rate (Qd)

Range: 500–800 mL/min

Counter-current flow maximizes concentration gradients throughout the dialyzer length. Standard 500 mL/min is adequate for most patients; rates >600–700 mL/min yield marginal improvements in small solute clearance.

Treatment Duration

Standard: 3–4 hours, 3x/week

Linear relationship with solute removal. Extended times improve phosphate clearance and allow gentler ultrafiltration rates (<10–13 mL/kg/hr).

Dialyzer Selection

Surface area: 1.0–2.5 m²

High-flux membranes improve beta-2 microglobulin clearance (11,800 Da) and reduce dialysis-related amyloidosis. High-flux is preferred for most patients.

Net Ultrafiltration

Range: 0.5–4.0 L/session

Based on interdialytic weight gain and dry weight target. UF rates >10–13 mL/kg/hr increase risk of intradialytic hypotension.

Anticoagulation

Standard: Heparin bolus + infusion

Prevents clotting in extracorporeal circuit. Adjust for bleeding risk. Citrate or saline flushes used when heparin is contraindicated.

Dialysate Electrolyte Composition

Electrolyte Typical Range Clinical Considerations
Sodium 135–145 mEq/L Higher Na supports hemodynamic stability during UF but increases interdialytic thirst and weight gain
Potassium 0–4 mEq/L Individualize based on pre-dialysis serum K; rapid shifts may trigger arrhythmias. See Rule of 8 below
Calcium 2.5–3.5 mEq/L Adjust for CKD-MBD status; patients on calcium-based binders may need lower dialysate Ca
Bicarbonate 32–40 mEq/L Corrects metabolic acidosis; avoid overcorrection causing post-dialysis alkalosis
Glucose 0–200 mg/dL Added for diabetic patients prone to hypoglycemia or when additional osmotic support needed during aggressive UF

The Rule of 8 for Dialysate Potassium

Serum K+ + Dialysate K+ = 8

This clinical shortcut guides dialysate potassium selection to avoid excessively rapid K removal and minimize cardiac arrhythmia risk.

Serum K = 6.0: Dialysate K = 2 mEq/L
Serum K = 5.5: Dialysate K = 2.5 mEq/L
Serum K = 5.0: Dialysate K = 3 mEq/L
Serum K = 4.0: Dialysate K = 4 mEq/L
Clinical Pearl: Aggressive potassium removal (large gradient) increases arrhythmia risk, especially in patients on digoxin or with LVH. When serum K >6.5, use a dialysate K of 2 but monitor closely for arrhythmias.

Clearance Formula

Clearance (K) = Blood Flow Rate (Qb) × Extraction Ratio

Extraction Ratio = (Cin − Cout) / Cin

Where Cin = arterial (inlet) blood concentration and Cout = venous (outlet) blood concentration. Clearance can never exceed Qb or Qd (whichever is lower). Higher extraction ratios indicate more efficient solute removal.

Dialysis Adequacy: Kt/V and URR

Kt/V (Fractional Clearance)

K = dialyzer clearance (mL/min)
t = treatment time (minutes)
V = urea distribution volume (mL)

HD target: Kt/V ≥ 1.2 per session

PD target: Weekly Kt/V ≥ 1.7

Single-pool vs. Equilibrated Kt/V: Single-pool assumes instantaneous equilibration and overestimates delivered dialysis. Equilibrated Kt/V accounts for urea rebound and is typically 10–15% lower.

URR (Urea Reduction Ratio)

URR = (Pre-BUN − Post-BUN) / Pre-BUN × 100%

Target: URR > 65%

Simpler calculation than Kt/V with similar clinical utility for monitoring adequacy.

Example: Pre-BUN 80, Post-BUN 20
URR = (80 − 20) / 80 × 100 = 75% (adequate)

Monthly Adequacy Monitoring

  • Kt/V measurement (target ≥1.2)
  • URR (target >65%)
  • Pre- and post-dialysis electrolytes and minerals
  • Hemoglobin/hematocrit (anemia management)
  • Phosphorus and PTH (mineral metabolism)
  • Albumin (nutritional status marker)

Urgent Dialysis Indications: AEIOU

When conservative management fails, urgent dialysis is indicated for life-threatening complications of kidney failure. The mnemonic AEIOU captures the major indications:

A

Acidosis

Severe metabolic acidosis (pH <7.1–7.2) refractory to bicarbonate therapy

E

Electrolytes

Refractory hyperkalemia (K >6.5 with ECG changes) unresponsive to medical management

I

Intoxication

Dialyzable toxins: methanol, ethylene glycol, lithium, salicylates, metformin

O

Overload

Volume overload with pulmonary edema refractory to diuretic therapy

U

Uremia

Uremic symptoms: encephalopathy, pericarditis, neuropathy, bleeding

High-Yield: Uremic pericarditis is an absolute indication for urgent dialysis. Uremic encephalopathy (asterixis, confusion, seizures) requires emergent initiation. Uremic bleeding responds to dialysis, desmopressin, and cryoprecipitate.

Vascular Access for Hemodialysis

The hierarchy of preferred access follows: AV Fistula > AV Graft > Tunneled Catheter > Temporary Catheter. Fistula First initiative targets ≥65% fistula prevalence in dialysis units.

AV Fistula (Gold Standard)

Construction: Direct artery-to-vein anastomosis (typically radial artery to cephalic vein)

Maturation: 6–12 weeks

Blood flow: 400–600+ mL/min

Advantages

  • Lowest infection rates
  • Superior longevity (10–15+ years)
  • Highest achievable Qb
  • Reduced thrombosis vs. grafts

Assessment

  • Bruit: Whooshing sound (turbulent flow) — normal finding
  • Thrill: Palpable vibration — normal finding
  • Loss of bruit/thrill: Suggests clotting or stenosis

AV Graft

Construction: Synthetic PTFE conduit connecting artery to vein

Maturation: 2–4 weeks

Advantages

  • Shorter maturation than fistula
  • Suitable when native vessels are inadequate

Disadvantages

  • Higher infection rates than fistulas
  • Increased thrombosis risk
  • Shorter functional lifespan
  • More prone to stenosis

Central Venous Catheters

Tunneled (Permcath): Dual-lumen, subcutaneous tunnel, Dacron cuff. Internal jugular preferred. Used as bridge therapy or when permanent access fails.

Temporary (Non-tunneled): For acute dialysis (<2–3 weeks). Internal jugular, femoral, or subclavian. Subclavian carries highest stenosis risk—avoid if future fistula planned.

Complications

  • Catheter-related bloodstream infections (~2.1 per 1,000 catheter-days)
  • Central venous stenosis/thrombosis
  • Mechanical dysfunction (fibrin sheath, kinking)

Vascular Access Complications

Complication Pathophysiology Clinical Features Management
Steal Syndrome AV access diverts excessive blood flow from distal extremity Digital ischemia, pain, numbness, coldness, tissue necrosis Access modification, banding, DRIL procedure, or closure in severe cases
Stenosis Neointimal hyperplasia at venous anastomosis or outflow Elevated venous pressures, prolonged bleeding, decreased Qb, arm swelling Angioplasty, stenting, or surgical revision
Thrombosis Usually secondary to underlying stenosis; low flow states Loss of thrill and bruit, inability to cannulate Thrombectomy (surgical or pharmacomechanical), address underlying stenosis
Infection Bacterial colonization; highest with catheters, lowest with fistulas Erythema, drainage, fever, bacteremia, sepsis Antibiotics; catheter exchange or removal; graft excision if abscess
High-Output Cardiac Failure Access flow >2 L/min increases cardiac output demand LVH, heart failure symptoms, pulmonary hypertension Access flow reduction (banding), revision, or closure
Aneurysm/Pseudoaneurysm Repeated cannulation weakens vessel wall Expanding pulsatile mass, risk of rupture Surgical repair; rotate cannulation sites (rope-ladder technique)

Intradialytic Complications

Intradialytic Hypotension (IDH) — Most Common (20–30% of treatments)

Pathophysiology

  1. UF removes fluid from intravascular compartment
  2. Vascular refill from interstitium cannot keep pace
  3. Despite total body fluid overload, circulating volume depletes
  4. Autonomic compensation impaired in uremia
  5. Warm dialysate and acetate cause peripheral vasodilation

Clinical Features

  • Symptomatic BP reduction
  • Cramping, nausea, vomiting
  • Dizziness, altered mental status
  • Muscle cramping (cellular dehydration)

Immediate Management

  1. Stop ultrafiltration (most effective initial step)
  2. Trendelenburg positioning (feet above heart)
  3. NS bolus 100–250 mL
  4. Hypertonic saline or mannitol (enhances plasma refilling)

Prevention Strategies

  • Accurate dry weight determination
  • UF rate <10–13 mL/kg/hr
  • Cool dialysate (35.5–36°C)
  • Higher dialysate sodium (sodium modeling)
  • Hold antihypertensives pre-dialysis
  • Midodrine 10 mg pre-dialysis for recurrent IDH
  • Extended treatment times
Key Concept — Vascular Refill: The rate of fluid mobilization from edematous tissues to the vascular compartment (typically 200–400 mL/hr) is the limiting factor. When UF exceeds refill capacity, intravascular depletion develops despite total body fluid excess. This explains why edematous patients still become hypotensive on dialysis.

Muscle Cramps

  • Mechanism: Rapid fluid shifts, electrolyte changes, cellular dehydration
  • Risk factors: Aggressive UF, large interdialytic weight gains, low Na dialysate
  • Management: Reduce UF rate, increase dialysate Na, stretch/massage, longer treatment times

Air Embolism

Life-threatening emergency. Air enters extracorporeal circuit through line disconnections, cracked tubing, or empty saline bag. Modern machines have air detectors, but vigilance is essential.
  • Symptoms: Sudden dyspnea, chest pain, cyanosis, cardiovascular collapse
  • Immediate management: Clamp venous line, place patient left lateral decubitus (Durant maneuver) and Trendelenburg, aspirate air from CVC if present, 100% O2

Hemolysis

Causes: Overheated dialysate, hypotonic dialysate, kinked blood lines, contaminated water supply (chloramine, copper), malfunctioning blood pump.
  • Signs: Port-wine colored blood in return line, back pain, chest tightness, hypotension, hyperkalemia
  • Management: Stop dialysis immediately, do NOT return blood (it contains free K from lysed cells), check dialysate composition and water quality

Dialysis Disequilibrium Syndrome (DDS)

Pathophysiology

Rapid removal of urea and other osmotically active solutes from blood during dialysis creates a transient osmotic gradient between plasma and the brain. The blood-brain barrier limits rapid equilibration, causing water to shift into brain cells.

  1. Rapid solute (urea) clearance from blood
  2. Blood osmolality drops quickly
  3. Brain retains idiogenic osmoles (organic osmolytes)
  4. Osmotic gradient drives water into brain tissue
  5. Cerebral edema develops

Clinical Manifestations

  • Mild: Headache, nausea, vomiting, restlessness
  • Moderate: Disorientation, blurred vision, muscle twitching
  • Severe: Seizures, obtundation, coma (rarely fatal)

Risk Factors

  • First dialysis treatments (highest risk)
  • Very high pre-dialysis BUN (>150 mg/dL)
  • Severe metabolic acidosis
  • Pediatric and elderly patients
  • Pre-existing CNS disease
  • Hyponatremia

Prevention Strategies

  • Shorter first treatments (2 hours, then gradually increase)
  • Lower blood flow rates initially (200 mL/min)
  • Target modest BUN reduction (<40% on first session)
  • Mannitol infusion (0.5–1 g/kg) to maintain plasma osmolality
  • Higher dialysate sodium (145–150 mEq/L)
  • Cool dialysate

Treatment

  • Stop dialysis or slow blood flow rate
  • IV mannitol (1 g/kg) or hypertonic saline (23.4%)
  • Benzodiazepines or phenytoin for seizures
  • CT head to exclude other causes (subdural hematoma, stroke)

First Dialysis in the Acutely Ill Patient

Initiating dialysis in a critically ill patient with severe uremia requires a careful approach to avoid disequilibrium syndrome and hemodynamic instability.

Key Principles

Parameter First Treatment Subsequent Treatments Rationale
Duration 2 hours Increase by 30–60 min each session to target 3–4 hrs Limits osmolality shift, reduces DDS risk
Blood flow 200 mL/min Increase by 50 mL/min each session to 300–400 Slower clearance rate prevents rapid osmotic shifts
BUN reduction target <30–40% Normal adequacy targets Aggressive reduction in severely uremic patients causes DDS
Dialysate Na 145–150 mEq/L Standard (140 mEq/L) Maintains plasma osmolality during urea removal
UF goal Modest (1–2 L max) Based on fluid status Hemodynamic instability is common; prioritize solute clearance over volume removal initially
Mannitol Consider 0.5–1 g/kg IV Usually not needed Counteracts osmotic gradient; prevents cerebral edema
Frequency Daily or every other day 3x/week when stable Frequent short treatments are safer than infrequent long ones in the initial period
Clinical Pearl: For patients with BUN >150 mg/dL, consider CRRT (continuous renal replacement therapy) or SLED (sustained low-efficiency dialysis) as alternatives for the initial treatment. These modalities provide gentler solute clearance over extended periods and are better tolerated hemodynamically in ICU patients.
Critical Reminder: Always assess for and address hyperkalemia before and during the first dialysis session. Potassium-related cardiac arrest is the most immediately life-threatening complication in patients presenting with severe AKI or ESKD. Obtain a 12-lead ECG and ensure continuous telemetry monitoring.

References

  1. Daugirdas JT, Blake PG, Ing TS, eds. Handbook of Dialysis. 5th ed. Wolters Kluwer; 2015.
  2. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. Am J Kidney Dis. 2015;66(5):884-930. PubMed
  3. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164. PubMed
  4. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int. 2011;79(2):250-257. PubMed
  5. Zepeda-Orozco D, Quigley R. Dialysis disequilibrium syndrome. Pediatr Nephrol. 2012;27(12):2205-2211. PubMed
  6. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2020;75(1 Suppl 1):A6-A7. PubMed
  7. Rayner HC, Zepel L, Fuller DS, et al. Recovery time, quality of life, and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2014;64(1):86-94. PubMed
  8. Chou JA, Streja E, Nguyen DV, et al. Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrol Dial Transplant. 2018;33(1):149-159. PubMed
  9. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol. 2004;15(2):477-486. PubMed
  10. Basile C, Pisano A, Lisi P, et al. High versus low dialysate sodium concentration in chronic haemodialysis patients: a systematic review and meta-analysis. Nephrol Dial Transplant. 2016;31(4):548-563. PubMed

Andrew Bland, MD, FACP, FAAP | University of Dubuque PA Program | Urine Nephrology Now

© 2025 | For educational purposes only

Also on this topic

The same subject at other levels of depth.